<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName></PublisherName>
				<JournalTitle>Iranian International Journal of Science(Not Publish)</JournalTitle>
				<Issn></Issn>
				<Volume>6</Volume>
				<Issue>0</Issue>
				<PubDate PubStatus="epublish">
					<Year>2005</Year>
					<Month>09</Month>
					<Day>23</Day>
				</PubDate>
			</Journal>
<ArticleTitle>-</ArticleTitle>
<VernacularTitle>-</VernacularTitle>
			<FirstPage></FirstPage>
			<LastPage></LastPage>
			<ELocationID EIdType="pii">30832</ELocationID>
			
			
			<Language>FA</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>A fully Bayesian approach for sample size determination for a clinical trial is presented in which the final decision whether to use the new treatment is taken by potential users and their medical advisers on the basis of the strength of the evidence provided by the trial. Data are assumed to come from two independent binomial distributions and the parameter of interest is  , where  and are two independent proportions. The optimal size is obtained by maximizing the expected net benefit function, which is the expected benefit from subsequent use of the new treatment minus the cost of the tria</Abstract>
			<OtherAbstract Language="FA">A fully Bayesian approach for sample size determination for a clinical trial is presented in which the final decision whether to use the new treatment is taken by potential users and their medical advisers on the basis of the strength of the evidence provided by the trial. Data are assumed to come from two independent binomial distributions and the parameter of interest is  , where  and are two independent proportions. The optimal size is obtained by maximizing the expected net benefit function, which is the expected benefit from subsequent use of the new treatment minus the cost of the tria</OtherAbstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Bayesian Approach</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Binomial Distribution</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Clinical trials</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Expected Net Benefit</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Sample size determination</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://iijs.ut.ac.ir/article_30832_846b59db06046ad679a5d34f4daccaaa.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
